NASDAQ:ACIU - AC Immune Stock Price, Price Target & More

$10.90 +0.20 (+1.87 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$10.70
Today's Range$10.61 - $10.90
52-Week Range$6.03 - $13.91
Volume23,209 shs
Average Volume61,196 shs
Market Capitalization$616.57 million
P/E Ratio-36.33
Dividend YieldN/A
Beta2.21

About AC Immune (NASDAQ:ACIU)

AC Immune logoAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's (AD), Parkinson's, down syndrome, and glaucoma diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACIU
CUSIPN/A
Phone41-21-345-9121

Debt

Debt-to-Equity RatioN/A
Current Ratio13.28%
Quick Ratio13.28%

Price-To-Earnings

Trailing P/E Ratio-36.33
Forward P/E Ratio-10.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.58 million
Price / Sales40.12
Cash FlowN/A
Price / CashN/A
Book Value$2.09 per share
Price / Book5.22

Profitability

EPS (Most Recent Fiscal Year)($0.30)
Net Income$-26,840,000.00
Net Margins-131.08%
Return on Equity-22.12%
Return on Assets-20.10%

Miscellaneous

Employees67
Outstanding Shares57,350,000

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings data on Tuesday, March, 20th. The company reported $0.06 earnings per share for the quarter. The business had revenue of $16.64 million for the quarter. AC Immune had a negative net margin of 131.08% and a negative return on equity of 22.12%. View AC Immune's Earnings History.

When is AC Immune's next earnings date?

AC Immune is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for AC Immune.

What price target have analysts set for ACIU?

2 analysts have issued 12 month price objectives for AC Immune's stock. Their predictions range from $14.00 to $18.00. On average, they expect AC Immune's share price to reach $16.00 in the next year. View Analyst Ratings for AC Immune.

Who are some of AC Immune's key competitors?

Who are AC Immune's key executives?

AC Immune's management team includes the folowing people:
  • Dr. Andrea Pfeifer, Co-Founder, Chief Exec. Officer and Director (Age 60)
  • Mr. Joerg Hornstein, Chief Financial Officer
  • Dr. Andreas Muhs Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 47)
  • Dr. Joseph O'Sullivan Ph.D., LL.M, Head of Bus. Devel.

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Has AC Immune been receiving favorable news coverage?

Press coverage about ACIU stock has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AC Immune earned a news impact score of 0.04 on Accern's scale. They also gave media coverage about the company an impact score of 43.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $10.90.

How big of a company is AC Immune?

AC Immune has a market capitalization of $616.57 million and generates $15.58 million in revenue each year. The company earns $-26,840,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. AC Immune employs 67 workers across the globe.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]


MarketBeat Community Rating for AC Immune (ACIU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AC Immune (NASDAQ:ACIU) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for AC Immune in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 46.79%. The high price target for ACIU is $18.00 and the low price target for ACIU is $14.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldBuyBuy
Consensus Rating Score: 2.502.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$14.00$18.00$21.50
Price Target Upside: 46.79% upside12.00% upside121.67% upside164.78% upside

AC Immune (NASDAQ:ACIU) Consensus Price Target History

Price Target History for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018HC WainwrightInitiated CoverageBuy$18.00HighView Rating Details
3/23/2018Credit Suisse GroupDowngradeOutperform -> Neutral$18.00 -> $14.00HighView Rating Details
12/13/2016Jefferies GroupReiterated RatingBuy$25.00N/AView Rating Details
11/26/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

AC Immune (NASDAQ:ACIU) Earnings History and Estimates Chart

Earnings by Quarter for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU) Earnings Estimates

2018 EPS Consensus Estimate: ($0.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.21)($0.10)($0.16)
Q2 20182($0.21)($0.11)($0.16)
Q3 20182($0.31)($0.17)($0.24)
Q4 20182($0.31)($0.18)($0.25)

AC Immune (NASDAQ ACIU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018N/AView Earnings Details
3/20/2018Q4 2017$0.06$16.64 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.20)($0.16)$4.18 million$1.12 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.07)($0.22)$4.16 million$0.76 millionViewN/AView Earnings Details
5/11/20173/31/2017($0.17)($0.17)$3.43 million$1.99 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AC Immune (NASDAQ:ACIU) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AC Immune (NASDAQ ACIU) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 19.48%
Insider Trading History for AC Immune (NASDAQ:ACIU)
Institutional Ownership by Quarter for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ ACIU) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

AC Immune (NASDAQ ACIU) News Headlines

Source:
DateHeadline
Will AC Immune SA’s (NASDAQ:ACIU) Earnings Grow Over The Next Few Years?Will AC Immune SA’s (NASDAQ:ACIU) Earnings Grow Over The Next Few Years?
finance.yahoo.com - April 20 at 4:22 PM
Brokerages Anticipate AC Immune SA (ACIU) to Post ($0.23) Earnings Per ShareBrokerages Anticipate AC Immune SA (ACIU) to Post ($0.23) Earnings Per Share
www.americanbankingnews.com - April 17 at 1:32 AM
AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimers diseaseAC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease
finance.yahoo.com - April 13 at 10:07 AM
AC Immune (ACIU) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAC Immune (ACIU) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:19 PM
AC Immune (ACIU) Downgraded by Zacks Investment ResearchAC Immune (ACIU) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 4:06 PM
AC Immune (ACIU) Earns Buy Rating from Analysts at HC WainwrightAC Immune (ACIU) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - April 5 at 11:27 AM
Jefferies Group Equities Analysts Reduce Earnings Estimates for AC Immune SA (ACIU)Jefferies Group Equities Analysts Reduce Earnings Estimates for AC Immune SA (ACIU)
www.americanbankingnews.com - April 5 at 9:22 AM
AC immune selects Tau candidates for Alzheimers diseaseAC immune selects Tau candidates for Alzheimer's disease
seekingalpha.com - April 5 at 8:49 AM
AC Immune SA (ACIU) to Post Q1 2018 Earnings of ($0.21) Per Share, Jefferies Group ForecastsAC Immune SA (ACIU) to Post Q1 2018 Earnings of ($0.21) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - April 4 at 6:28 AM
Wired News – MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine DependenceWired News – MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence
finance.yahoo.com - April 3 at 9:59 AM
 Brokerages Set $26.00 Target Price for AC Immune SA (ACIU) Brokerages Set $26.00 Target Price for AC Immune SA (ACIU)
www.americanbankingnews.com - April 2 at 9:22 PM
 AC Immune SA (ACIU) Given Average Recommendation of "Strong Buy" by Analysts AC Immune SA (ACIU) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - March 30 at 7:42 AM
AC Immune (ACIU) Downgraded to "Neutral" at Credit Suisse GroupAC Immune (ACIU) Downgraded to "Neutral" at Credit Suisse Group
www.americanbankingnews.com - March 23 at 6:49 PM
AC Immune Promising On Alzheimers, But Light On Short-Term Catalysts, Says Credit SuisseAC Immune Promising On Alzheimer's, But Light On Short-Term Catalysts, Says Credit Suisse
finance.yahoo.com - March 23 at 4:13 PM
AC Immune posts 4Q profitAC Immune posts 4Q profit
finance.yahoo.com - March 21 at 10:52 AM
AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinsons diseaseAC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease
finance.yahoo.com - March 15 at 9:35 AM
 AC Immune SA (ACIU) Receives Average Recommendation of "Strong Buy" from Brokerages AC Immune SA (ACIU) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 14 at 3:10 AM
AC Immune (ACIU) Upgraded to Hold at BidaskClubAC Immune (ACIU) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - March 10 at 7:10 PM
Comparing AEterna Zentaris (AEZS) and AC Immune (ACIU)Comparing AEterna Zentaris (AEZS) and AC Immune (ACIU)
www.americanbankingnews.com - March 10 at 1:12 AM
Zacks: Analysts Set $26.00 Price Target for AC Immune SA (ACIU)Zacks: Analysts Set $26.00 Price Target for AC Immune SA (ACIU)
www.americanbankingnews.com - March 8 at 9:06 PM
AC Immune (ACIU) Scheduled to Post Earnings on ThursdayAC Immune (ACIU) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:10 AM
BidaskClub Downgrades AC Immune (ACIU) to SellBidaskClub Downgrades AC Immune (ACIU) to Sell
www.americanbankingnews.com - March 4 at 12:16 AM
AC Immune (ACIU) Downgraded by BidaskClub to "Hold"AC Immune (ACIU) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 18 at 4:22 PM
Zacks: Analysts Set $23.50 Price Target for AC Immune SA (ACIU)Zacks: Analysts Set $23.50 Price Target for AC Immune SA (ACIU)
www.americanbankingnews.com - February 18 at 5:10 AM
AC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD ConferenceAC Immune to Participate in Two Investor Conferences and Provide Scientific Updates at AAT-AD/PD Conference
finance.yahoo.com - February 6 at 9:00 AM
AC Immune (ACIU) Stock Rating Upgraded by Zacks Investment ResearchAC Immune (ACIU) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 5 at 4:54 PM
AC Immune (ACIU) Lowered to Buy at BidaskClubAC Immune (ACIU) Lowered to Buy at BidaskClub
www.americanbankingnews.com - February 3 at 1:38 PM
AC Immune SA (ACIU) Expected to Announce Quarterly Sales of $12.93 MillionAC Immune SA (ACIU) Expected to Announce Quarterly Sales of $12.93 Million
www.americanbankingnews.com - January 31 at 2:58 AM
 Brokerages Set $23.50 Target Price for AC Immune SA (ACIU) Brokerages Set $23.50 Target Price for AC Immune SA (ACIU)
www.americanbankingnews.com - January 31 at 1:18 AM
Analyzing AC Immune (ACIU) and Idera Pharmaceuticals (IDRA)Analyzing AC Immune (ACIU) and Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - January 29 at 1:14 PM
AC Immune (ACIU) Upgraded by BidaskClub to "Strong-Buy"AC Immune (ACIU) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - January 27 at 4:28 PM
Critical Analysis: AC Immune (ACIU) versus The CompetitionCritical Analysis: AC Immune (ACIU) versus The Competition
www.americanbankingnews.com - January 25 at 3:14 PM
AC Immune (ACIU) Cut to "Buy" at BidaskClubAC Immune (ACIU) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - January 21 at 4:58 PM
Brokerages Expect AC Immune SA (ACIU) to Post ($0.09) Earnings Per ShareBrokerages Expect AC Immune SA (ACIU) to Post ($0.09) Earnings Per Share
www.americanbankingnews.com - January 21 at 5:46 AM
AC Immune SA (ACIU) Expected to Earn FY2017 Earnings of ($0.52) Per ShareAC Immune SA (ACIU) Expected to Earn FY2017 Earnings of ($0.52) Per Share
www.americanbankingnews.com - January 19 at 8:16 AM
Contrasting AC Immune (ACIU) & The CompetitionContrasting AC Immune (ACIU) & The Competition
www.americanbankingnews.com - January 18 at 7:44 PM
 Analysts Anticipate AC Immune SA (ACIU) Will Announce Quarterly Sales of $12.93 Million Analysts Anticipate AC Immune SA (ACIU) Will Announce Quarterly Sales of $12.93 Million
www.americanbankingnews.com - January 16 at 12:08 AM
Contrasting AC Immune (ACIU) and Its PeersContrasting AC Immune (ACIU) and Its Peers
www.americanbankingnews.com - January 9 at 3:42 PM
Zacks: AC Immune SA (ACIU) Given $23.00 Average Price Target by AnalystsZacks: AC Immune SA (ACIU) Given $23.00 Average Price Target by Analysts
www.americanbankingnews.com - January 5 at 5:34 PM
Comparing AC Immune (ACIU) & Its PeersComparing AC Immune (ACIU) & Its Peers
www.americanbankingnews.com - January 3 at 7:06 PM
Zacks: AC Immune SA (ACIU) Given Consensus Rating of "Strong Buy" by AnalystsZacks: AC Immune SA (ACIU) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - January 2 at 9:10 PM
 Brokerages Expect AC Immune SA (ACIU) Will Post Quarterly Sales of $12.93 Million Brokerages Expect AC Immune SA (ACIU) Will Post Quarterly Sales of $12.93 Million
www.americanbankingnews.com - December 29 at 4:26 PM
AC Immune (ACIU) Upgraded to "Strong-Buy" by BidaskClubAC Immune (ACIU) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - December 28 at 8:42 PM
Analyzing AC Immune (ACIU) & Its RivalsAnalyzing AC Immune (ACIU) & Its Rivals
www.americanbankingnews.com - December 28 at 9:29 AM
AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 9:43 AM
AC Immune SA (NASDAQ:ACIU) And The Healthcare Industry Prospect For 2017AC Immune SA (NASDAQ:ACIU) And The Healthcare Industry Prospect For 2017
finance.yahoo.com - December 19 at 10:48 AM
Zacks: AC Immune  SA (ACIU) Given Average Recommendation of "Strong Buy" by AnalystsZacks: AC Immune SA (ACIU) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 18 at 1:52 AM
AC Immune  SA (ACIU) Short Interest UpdateAC Immune SA (ACIU) Short Interest Update
www.americanbankingnews.com - December 15 at 2:38 AM
AC Immune  SA (ACIU) Expected to Announce Quarterly Sales of $12.93 MillionAC Immune SA (ACIU) Expected to Announce Quarterly Sales of $12.93 Million
www.americanbankingnews.com - December 11 at 5:00 AM
Zacks: AC Immune  SA (ACIU) Given Consensus Rating of "Strong Buy" by AnalystsZacks: AC Immune SA (ACIU) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 3 at 9:26 AM

SEC Filings

AC Immune (NASDAQ:ACIU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AC Immune (NASDAQ:ACIU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AC Immune (NASDAQ ACIU) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.